Seoul, Republic of Korea – A groundbreaking artificial intelligence (AI) imaging endpoint has demonstrated a remarkable ability to identify early, significant treatment effects in lung cancer patients, potentially revolutionizing how treatment efficacy is assessed and treatment plans are adjusted. The AI system, developed by Altis Labs and named IPRO (Imaging Prognostic Outcome), has outperformed traditional imaging endpoints in a pivotal Phase III clinical trial, offering a faster and more accurate prediction of patient outcomes.
Unveiling the Power of IPRO: A New Era in Oncology Trial Assessment
In the fight against advanced non-small-cell lung cancer (NSCLC), where time is of the essence, the ability to quickly and accurately gauge a patient’s response to therapy is paramount. Johnson & Johnson’s Phase III MAIRPOSA study (NCT04487080), investigating the efficacy of Rybrevant (amivantamab) in combination with Lazertinib for patients with epidermal growth factor receptor (EGFR)-mutated NSCLC, provided a crucial testing ground for Altis Labs’ innovative AI imaging endpoint.
The MAIRPOSA study, a cornerstone in the evaluation of these targeted therapies, involved the analysis of approximately 10,000 radiology scans. Altis Labs’ IPRO software meticulously analyzed these scans, generating prognostic outcome measures for each patient at the outset of the study (baseline) and at various points during treatment. This comprehensive analysis allowed for a deeper understanding of treatment impact beyond simple tumor size reduction.
IPRO’s Superiority Over Traditional Endpoints: A Detailed Look
The core innovation of IPRO lies in its sophisticated approach to analyzing medical images. Unlike traditional methods that primarily focus on measuring the size of target lesions – a metric captured by the Response Evaluation Criteria in Solid Tumours (RECIST) – IPRO delves deeper. The AI system analyzes three-dimensional CT scans, going beyond the two-dimensional measurements of RECIST. This allows IPRO to identify and quantify a multitude of prognostic imaging biomarkers that are not captured by conventional assessments. These biomarkers encompass crucial aspects such as tumor burden, body composition, and organ health, all of which are known to significantly influence multifactorial survival outcomes.
In the MAIRPOSA study, IPRO defined a "response" as a notable improvement, specifically a 50% enhancement in the IPRO-μ score relative to the baseline assessment. The "treatment effect" was then quantified by comparing the IPRO Response Rate ratio between the investigational treatment arm and the control arm at key early imaging assessment points.
The results were striking. IPRO demonstrated a clear advantage, indicating a favorable response to the investigational treatment beginning as early as week 16 and continuing through subsequent assessment periods. In stark contrast, the RECIST-based objective response rate (ORR), a standard metric in oncology trials, failed to anticipate the significant overall survival (OS) benefit that was ultimately observed. This discrepancy highlights a critical limitation of traditional endpoints: their potential to lag behind the actual clinical benefit experienced by patients.
Further reinforcing IPRO’s predictive power, the analysis of pooled, patient-level IPRO trajectories over time revealed a consistent correlation between image-based prognostics and survival. IPRO deterioration was invariably linked to a detrimental impact on OS, while IPRO improvement was consistently associated with a beneficial effect on OS. This direct correlation underscores IPRO’s capacity to serve as a more sensitive and earlier indicator of treatment success or failure.
Chronology of Innovation: From Concept to Clinical Validation
The development of IPRO is the culmination of years of research and refinement in the field of AI-driven medical imaging. Altis Labs, a company at the forefront of this technological revolution, has focused on creating AI tools that can unlock the wealth of information contained within medical scans, information that often goes unappreciated by human interpretation alone.
The MAIRPOSA study, initiated in July 2020, provided a critical opportunity to validate IPRO’s capabilities in a real-world clinical setting. The study’s design, incorporating the investigational combination of Rybrevant and Lazertinib, targeted a specific and aggressive form of lung cancer – EGFR-mutated advanced NSCLC. This patient population often faces limited treatment options and requires precise and timely therapeutic interventions.
The data presented at the World Conference on Lung Cancer (WCLC) 2026 in Seoul, Republic of Korea, marked a significant milestone, showcasing the robust performance of IPRO. The conference, a premier gathering for lung cancer researchers and clinicians worldwide, provided a platform for sharing cutting-edge discoveries and fostering collaborative advancements in the field.
Altis Labs’ presentation at WCLC 2026 not only highlighted IPRO’s analytical prowess but also articulated its potential to reshape the landscape of clinical trial design and execution. The ability to detect meaningful clinical benefit earlier in the trial process could lead to more efficient trial designs, faster drug approvals, and ultimately, quicker access to life-saving treatments for patients.
Supporting Data: Quantifying the Predictive Power
The quantitative evidence emerging from the MAIRPOSA study is compelling. While specific numerical values for the IPRO-μ score improvement and the ratio differences are proprietary and were presented at the WCLC conference, the qualitative findings are clear:
- Early Signal Detection: IPRO identified a positive treatment effect at week 16, a critical early time point in a lung cancer trial. This is significantly earlier than the typical assessment periods for RECIST-based ORR, which often require longer observation to demonstrate meaningful changes.
- Correlation with Overall Survival: The consistent association between IPRO trajectories (improvement and deterioration) and patient OS provides strong validation for its prognostic capabilities. This suggests that IPRO can act as a reliable surrogate for long-term outcomes, a highly sought-after attribute in oncology endpoints.
- Beyond Tumor Size: By analyzing multiple prognostic imaging biomarkers, IPRO offers a more holistic assessment of a patient’s response and overall health status. This multidimensional approach is crucial, as treatment success is influenced by more than just the shrinkage of a tumor.
Felix Baldauf-Lenschen, Founder and CEO of Altis Labs, eloquently summarized the significance of these findings: "This readout proves that AI can anticipate meaningful clinical benefit that traditional imaging endpoints like ORR may fail to detect." This statement underscores the transformative potential of IPRO and similar AI-driven tools in accelerating the understanding of treatment efficacy.
Official Responses and the Future of Clinical Trials
The implications of IPRO’s success extend far beyond the confines of the MAIRPOSA study. Regulatory bodies and pharmaceutical companies are increasingly recognizing the limitations of traditional endpoints and are actively seeking innovative solutions to improve the efficiency and accuracy of clinical trials.
The US Food and Drug Administration (FDA) has long considered overall survival (OS) as the gold standard endpoint in oncology trials. In recognition of its importance, the FDA released draft guidance last year recommending OS as a key pre-specified endpoint in all cancer clinical trials. However, OS can take a considerable amount of time to mature, potentially delaying the approval of promising new therapies.
AI-powered imaging endpoints like IPRO offer a compelling solution by providing earlier signals of benefit. By detecting potential treatment failure at earlier time points, physicians will be able to amend a patient’s treatment plan, potentially improving their prognosis. This proactive approach could not only benefit individual patients but also streamline the drug development process.
Pharmaceutical companies are keenly interested in leveraging AI to optimize their clinical development strategies. The ability to identify non-responders earlier can lead to more efficient patient stratification, reduced trial costs, and a faster path to market for successful drugs. Johnson & Johnson’s participation in the MAIRPOSA study with Altis Labs’ IPRO demonstrates a commitment to exploring and embracing these advanced technologies.
Implications: A Paradigm Shift in Cancer Care
The successful validation of Altis Labs’ IPRO imaging endpoint heralds a significant paradigm shift in how cancer treatments are evaluated and how patients are managed. The implications are far-reaching:
- Earlier Intervention and Personalized Medicine: The ability to detect treatment failure at an earlier stage empowers physicians to intervene more rapidly. This means patients who are not responding to a particular therapy can be transitioned to alternative treatments sooner, potentially preventing disease progression and improving their chances of survival. This aligns perfectly with the principles of personalized medicine, where treatment is tailored to the individual patient’s needs and predicted response.
- Accelerated Drug Development: For pharmaceutical companies, IPRO offers a powerful tool to accelerate the drug development process. By providing earlier insights into treatment efficacy, it can help identify promising candidates more quickly, optimize trial designs, and potentially reduce the duration and cost of clinical development. This could lead to faster availability of new and improved cancer therapies for patients.
- Enhanced Clinical Trial Design: The insights gained from IPRO can inform the design of future clinical trials. Researchers can potentially design trials with earlier interim analyses based on IPRO readouts, allowing for quicker decision-making regarding trial continuation or modification. This could lead to more efficient and ethical trial execution.
- Deeper Understanding of Disease Biology: The multidimensional data generated by IPRO, analyzing not just tumor size but also tumor burden, body composition, and organ health, provides a richer understanding of the complex biological processes involved in cancer and its response to treatment. This deeper understanding can fuel further research and the development of novel therapeutic strategies.
- Democratization of Advanced Diagnostics: As AI technologies become more sophisticated and accessible, they have the potential to democratize advanced diagnostic capabilities. This could lead to wider adoption of AI-powered imaging analysis in clinical practice, benefiting patients in various healthcare settings.
In conclusion, Altis Labs’ IPRO imaging endpoint represents a significant leap forward in the evaluation of cancer treatments. Its ability to detect early treatment effects with greater accuracy than traditional methods holds the promise of transforming clinical trial design, accelerating drug development, and ultimately, improving patient outcomes in the ongoing battle against lung cancer and potentially other malignancies. As AI continues to integrate into medical diagnostics, the future of oncology promises to be more precise, personalized, and effective.
About the Author
